Rivastigmine Bitartrate Capsules

The pathological changes of Alzheimer's disease mainly involve the cholinergic neural pathways that radiate from the base of the forebrain to the cerebral cortex and hippocampus. These pathways are known to be related to attention, learning ability, memory and other cognitive processes. Rivastigmine bitartrate is an amino acid selective inhibitor of acetyl and butyrylcholinesterase in the brain that promotes cholinergic nerve conduction by delaying the degradation of acetylcholine released by fully functional cholinergic neurons. Animal experimental data show that rivastigmine bitartrate can increase the available acetylcholine in the cerebral cortex and hippocampus. Therefore, this product can improve cholinergic-mediated cognitive dysfunction in patients with Alzheimer's disease. Bitartrate

Chemical name: (S)-N-ethyl-N-methyl-3-[l-(dimethylamino)ethyl]-phenylcarbamate, hydrogen-(2R,3R)-tartaric acid Inactive ingredients: gelatin, red iron oxide (E172), yellow iron oxide (E172), magnesium stearate, methylhydroxypropyl cellulose, microcrystalline cellulose, red iron oxide (E172), printing ink

This product is a capsule, and the contents are off-white to slightly yellow powder.

Used to treat symptoms of mild to moderate Alzheimer's dementia.

Dosage: Twice a day, with breakfast and dinner. Starting dose: 1.5 mg, twice a day. Increasing dose: The recommended starting dose is 1.5 mg, twice a day; if the patient tolerates this dose well after taking it for at least 4 weeks, the dose can be increased to 3 mg, twice a day; when the patient tolerates this dose well after continuing to take it for at least 4 weeks, the dose can be gradually increased to 4.5 mg, or even 6 mg, twice a day. If side effects (such as nausea, vomiting, abdominal pain, or loss of appetite) or weight loss occur during treatment, the daily dose should be reduced to a dose that the patient can tolerate. Maintenance dose: 1.5-6 mg/time, twice a day. Patients who achieve the best therapeutic effect should maintain their highest and well-tolerated dose. Maximum recommended dose: 6 mg/time, twice a day

The most commonly reported adverse drug reactions are gastrointestinal reactions, including nausea (38%) and vomiting (23%), especially during the dose-increasing period. In clinical trials, it was found that female patients were more prone to gastrointestinal reactions and weight loss. One patient who took this product and took several other drugs at the same time developed Stevens-Johnson syndrome. In the initial stage of treatment, the incidence of adverse reactions is higher than in the maintenance stage. In the event of severe intolerance (such as severe nausea, vomiting, etc.), you should consider taking it three times a day. Treatment with this product does not cause changes in any laboratory test items, including liver function or electrocardiogram, so no special monitoring is required.

Patients with known hypersensitivity to rivastigmine, other amino acid derivatives or other ingredients of the formula are contraindicated to use this product. No relevant studies have been conducted. Exelon is contraindicated for patients with severe liver damage.

Precautions for children: This product is not recommended for children. Precautions for pregnancy and lactation: Pregnancy: Animal experiments have shown that rivastigmine has no teratogenic effect. Because there is still a lack of safety test data on the use of this product during human pregnancy, pregnant women should weigh the pros and cons when taking this product. Lactation: It is not clear whether this product is secreted from human breast milk. However, in animals, rivastigmine can be secreted from breast milk. Therefore, patients taking this product should stop breastfeeding. Accordingly, patients who are breastfeeding should not take this product. Precautions for the elderly: Although the bioavailability of rivastigmine in the elderly is higher than that in young healthy volunteers, the results of trials on Alzheimer's patients aged 50-92 years showed that the bioavailability of rivastigmine does not change with age.

Because of their pharmacological effects, cholinesterase inhibitors may have vagal effects on heart rate. Therefore, as with other cholinergic drugs, caution must be exercised when administering this drug to patients with sick sinus syndrome (SSS) or other heart blocks (see

Store below 30℃.

6.0mg*28s

48 months